Key points are not available for this paper at this time.
Repurposed drugs with host-directed antiviral and immunomodulatory properties have shown promise in the treatment of COVID-19, but few trials have studied combinations of these agents. The aim of this trial was to assess the effectiveness of affordable, widely available, repurposed drugs used in combination for treatment of COVID-19, which may be particularly relevant to low-resource countries.
Wannigama et al. (Thu,) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: